CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses
Research and development	$ 2,288	$ 3,989
General and administrative	1,407	1,303
Total operating expenses	3,695	5,292
Net operating loss	(3,695)	(5,292)
Other income
Change in fair value of warrant liability	538
Interest income		19
Total other income	538	19
Net loss	$ (3,157)	$ (5,273)
Net Loss Per Share, Basic
Net loss per share, basic	$ (4.88)	$ (13.25)
Weighted average number of common shares outstanding, basic	647	398
Net Loss Per Share, Diluted
Net loss per share, diluted	$ (4.88)	$ (13.25)
Weighted average number of common shares outstanding, diluted	647	398